ArticleFrontiers in medicine2026
The effect of iron treatment on fetal fraction according to gestational weeks in maternal anemia.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The aim of this study was to evaluate the effects of iron (Fe) supplementation in maternal anemia on fetal fraction (FF) according to different gestational ages (GA) in pregnancies undergoing non-invasive prenatal testing (NIPT). FF is one of the key parameters that directly determines the analytical reliability of NIPT. Therefore, understanding the impact of hematologic and treatment-related variables on FF is important for optimal test timing and for minimizing false-negative results. Methods: This retrospective, single-center study included 308 pregnant women who underwent NIPT between January 2020 and December 2025. Cases with obesity, multiple pregnancies, Results: The median maternal age was 33.5 years, and the median GA was 14.43 weeks. A moderate positive correlation was observed between GA and FF ( Conclusion: Although crude analyses suggested lower FF values among women receiving Fe supplementation after 16 weeks of gestation, multivariable regression analysis indicated that GA remained the primary determinant of FF. Therefore, the apparent association between Fe supplementation and FF likely reflects underlying GA-related and hematologic differences rather than a direct effect of Fe therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.